ArticleOncoTargets and therapy2016
Clinical efficacy of computed tomography-guided iodine-125 seed implantation therapy in patients with advanced spinal metastatic tumors.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- One case of iodine-125 therapy - A new minimally invasive treatment of intrahepatic cholangiocarcinoma.Open life sciences · 2022Article
- Palliative local treatment of bone metastases by 125I seed brachytherapy under DynaCT guidance: single-center experience.Diagnostic and interventional radiology (Ankara, Turkey) · 2021Article
- Iodine-125 seed implantation combined with arterial chemoembolization therapy for pain palliation in metastatic bone cancer: a retrospective study.Cancer biology & therapy · 2019Article
- CT-GuidedBioMed research international · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to examine the safety and clinical efficacy of computed tomography (CT)-guided radioactive iodine-125 ((125)I) seed implantation treatment in patients with spinal metastatic tumors.
methodsWe retrospectively analyzed 20 cases of spinal metastatic tumors, including nine men and eleven women aged 50-79 years (mean age: 61.1 years). We used treatment planning system (TPS) to construct three-dimensional images of the spinal metastatic tumors and to determine what number and dose rate distribution to use for the (125)I seeds. The matched peripheral dose of the (125)I seed implantation was 90-130 Gy. Twenty-four spinal metastatic tumors were treated by CT-guided radioactive (125)I seed implantation. A median of 19 (range: 4-43) (125)I seeds were implanted.
resultsTwenty cases were followed for a median of 15.3 months (range: 7-32 months). The rate of pain relief was 95%. The median control time for all of the patients was 12.5 months. The 3-, 6-, and 12-month cumulative local control rates were 100%, 95%, and 60%, respectively. The median survival time for all of the patients was 16 months. The cumulative 6- and 12-month survival rates were 100% and 78.81%, respectively. No major complications were observed. No (125)I seeds were lost or migrated to other tissues or organs.
conclusionCT-guided radioactive (125)I seed implantation is a safe, effective, and minimally invasive method for the treatment of patients with spinal metastatic tumors. It is a possible alternative therapy for the treatment of spinal metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.